Johnson&Johnson Ebola vaccine to start clinical trials in early 2015
Scientists will fast-track tests on another Ebola vaccine, this time from Johnson & Johnson, in another sign that the world's worst outbreak of the virus is mobilising research into the deadly disease.
J&J said on Thursday that clinical trials of its new vaccine, which includes technology from Danish biotech firm Bavarian Nordic, would commence in early 2015.
The move follows a decision to begin initial human testing of a GlaxoSmithKline vaccine this month and plans to test one developed by Canadian government scientists, which has been licensed to NewLink Genetics, in the autumn.
Human tests on the J&J vaccine were previously not expected to start until late 2015 or early 2016.
